Oral Administration of β-Lactamase Preserves Colonization Resistance of Piperacillin-Treated Mice

Journal of Infectious Diseases

Volumn 188, Issue 10, 2003, Pages 1605-1609

  Stiefel, Usha ^a   Pultz, Nicole J ^b   Harmoinen, Jaana ^c,d   Koski, Pertti ^d   Lindevall, Kai ^d   Helfand, Marion S ^b   Donskey, Curtis J ^b,e  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

^d Ipsat Therapies Ltd   (Finland)

^e LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; PIPERACILLIN; RECOMBINANT ENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL OVERGROWTH; CONTROLLED STUDY; DRUG EXCRETION; HOSPITAL INFECTION; INOCULATION; INTESTINE FLORA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CANDIDA GLABRATA; CANDIDIASIS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DNA, BACTERIAL; DNA, FUNGAL; DRUG SYNERGISM; ENTEROCOCCUS FAECIUM; FECES; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; PIPERACILLIN; POLYMERASE CHAIN REACTION;

EID: 0346645798     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/379153     Document Type: Article

References (22)

1. Vollaard EJ, Clasener HAL. Colonization resistance. Antimicrob Agents Chemother 1994; 38:409-14.
2. Nord CE, Heimdahl A, Kager L. Antimicrobial induced alterations of the human oropharyngeal and intestinal microflora. Scand J Infect Dis Suppl 1986; 49:64-72.
3. Bodey GP, Fainstein V, Garcia I, Rosenbaum B, Wong Y. Effect of broad-spectrum cephalosporins on the microbial flora of recipients. J Infect Dis 1983; 148:892-7.
4. Pavia AT, Shipman LD, Wells JG, et al. Epidemiologic evidence that prior antimicrobial exposure decreases resistance to infection by antimicrobial- sensitive Salmonella. J Infect Dis 1990; 161:255-60.
5. Wilson KH. The microecology of Clostridium difficile. Clin Infect Dis 1993; 16(Suppl 4):S214-8.
6. Donskey CJ, Hanrahan JA, Hutton RA, Rice LB. Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J Infect Dis 1999; 180:384-90.
7. Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000; 343:1925-32.
8. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162-71.
9. Samonis G, Gikas A, Anaissie EJ, et al. Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrob Agents Chemother 1993; 37:51-3.
10. Medeiros AA. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin Infect Dis 1997; 24(Suppl 1):S19-45.
11. Chachaty E, Depitre C, Mario N, et al. Presence of Clostridium difficile and antibiotic and β-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo. Antimicrob Agents Chemother 1992; 36:2009-13.
12. Stark C, Edlund C, Hedberg M, Nord CE. Induction of β-lactamase production in the anaerobic microflora by cefoxitin. Clin Infect Dis 1995; 20(Suppl 2):S350-1.
13. Leonard F, Andremont A, Leclerq B, Labia R, Tancrede C. Use of β-lactamase-producing anaerobes to prevent ceftriaxone from degrading intestinal resistance to colonization. J Infect Dis 1989; 160:274-80.
14. Chachaty E, Bourneix C, Renaard S, Bonnay M, Andremont A. Shedding of Clostridium difficile, fecal β-lactamase activity, and gastrointestinal symptoms in 51 volunteers treated with oral cefixime. Antimicrob Agents Chemother 1993; 37:1432-5.
15. Neugebauer K, Sprengel R, Schaller H. Penicillinase from Bacillus licheniformis: nucleotide sequence of the gene and implications for the biosynthesis of a secretory protein in a gram-positive bacterium. Nucleic Acids Res 1981; 9:2577-88.
16. Harmoinen J, Vaali K, Lindevall K, Westermarck E. Enzymic degradation of beta-lactam antibiotic, ampicillin, in the gut: a novel treatment modality. J Antimicrob Chemother 2003; 51:361-5.
17. Freireich E, Gehan E, Rall D, Schmidt L, Skipper H. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother Rep 1966; 50:219-44.
18. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard no. M7-A3. Wayne, PA: National Committee for Clinical Laboratory Standards, 1993.
19. Donskey CJ, Schreiber JR, Jacobs MJ, et al. A polyclonal outbreak of predominantly VanB vancomycin-resistant enterococci in northeast Ohio. Northeast Ohio Vancomycin-Resistant Enterococcus Surveillance Program. Clin Infect Dis 1999; 29:573-9.
20. Muyzer G, De Waal EC, Uitterlinden AG. Profiling of complex microbial populations by denaturing gradient gel electrophoresis analysis of polymerase chain reaction-amplified genes coding for 16S rRNA. Appl Environ Microbiol 1993; 59:695-700.
21. Freter R, Brickner H, Botney M, Cleven D, Aranki A. Mechanisms that control bacterial populations in continuous-flow culture models of mouse large intestinal flora. Infect Immun 1983; 39:676-85.
22. Freter R, Brickner H, Fekete J, Vickerman MM, Carey KE. Survival and implantation of Escherichia coli in the intestinal tract. Infect Immun 1983; 39:686-703.